Breakingviews - Breakdown: The scramble for a Covid-19 vaccine
NEW YORK/LONDON (Reuters Breakingviews) - Pharmaceutical groups such as AstraZeneca and Pfizer may soon get regulatorsâ€™ blessing for new coronavirus inoculations. A successful vaccine could ease a crisis that the Congressional Budget Office estimates will cost the United States alone some $8 trillion. Yet doubts over efficacy will linger, and manufacturing challenges mean poorer countries may have to wait. The reward for drugmakers is equally uncertain.
